Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncopeptides AB ( (SE:ONCO) ) just unveiled an announcement.
Oncopeptides plans to seek a Type II variation from the European Medicines Agency to expand Pepaxti’s label from fourth-line to third-line multiple myeloma treatment, potentially doubling its eligible patient population in Europe. Management believes a broader indication, backed by Phase 3 OCEAN data and evolving treatment standards, could significantly increase the drug’s commercial potential beyond the previously communicated SEK 1.5 billion market opportunity and further entrench the company in the competitive myeloma landscape.
The company expects initial regulatory feedback before the end of 2026 and a final European Commission decision in the first half of 2027, a timeline that will be closely watched by investors given its implications for revenue growth. Oncopeptides is engaging investors and analysts through a dedicated webcast, signaling the strategic importance of this label expansion effort for its long-term positioning in oncology and for stakeholders exposed to the success of Pepaxti.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotechnology company specializing in targeted therapies for difficult-to-treat cancers, built around its proprietary Peptide Drug Conjugate and SPiKE technology platforms. The company’s flagship drug Pepaxti, a peptide-conjugated cytotoxic agent for multiple myeloma, is being commercialized in Europe with regional partnerships and supported by a workforce of about 80 employees across several EU markets.
Average Trading Volume: 3,205,383
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK491.4M
See more data about ONCO stock on TipRanks’ Stock Analysis page.